This study is currently recruiting participants.
A phase 2, double-masked, randomized, parallel-group study to investigate the safety, tolerability and efficacy of GSK933776 in adult patients with geographic atrophy (GA) due to age-related macular degeneration (AMD).
1. Adult patients >55 years of age inclusive at the time of signing the informed consent.
2. Evidence of AMD confirmed by the presence of at least 1 druse >125 μm diameter in either eye.
3. Well-demarcated GA due to AMD of total area 1.9-17 mm2 measured on color
fundus photographs and fundus autofluorescence in the study eye.
4. Best-corrected ETDRS visual acuity score (approximately 20/200 Snellen VA equivalent) in the study eye. If both eyes are eligible for the study, the eye with the better BCVA score is selected as the study eye.
Dr. Richard Rosen, Retina Vitreous Specialist
Melissa Rivas, Research Coordinator at 212-614-8386
Home > Current Research > Clinical Trials in Ophthalmology >Geographic Atrophy AMD Study